Compass pathways stock forecast.
The average price target is $46.83, with a high forecast of $120.00 and a low forecast of $19.00. ... The current consensus among 5 investment analysts is to buy stock in COMPASS Pathways. This Buy consensus rating has held steady for over two years. Past Monthly Recommendations.
Latest CMPS News. View. COMPASS Pathways (CMPS, $5.98) entered Downtrend as Momentum indicator drops below 0 level on Nov 30, 2023. Tickeron - Stocks • 3 days ago. Compass Pathways to participate in upcoming Evercore investor conference. Globe Newswire • 10 days ago.3 พ.ค. 2564 ... Did you miss out on being an early investor in the Cannabis Boom? Investing in Compass Pathways stock ($CMPS) may be your golden ticket.3 พ.ค. 2564 ... Did you miss out on being an early investor in the Cannabis Boom? Investing in Compass Pathways stock ($CMPS) may be your golden ticket.COMPASS Pathways (NASDAQ: CMPS) has seen its earnings outlook for FY2023 revised by Cantor Fitzgerald. The equities researchers at Cantor Fitzgerald have raised their EPS estimates, predicting that the company will now earn ($2.08) per share for the year, up from their previous forecast of ($2.24).
Compass Pathways to participate in upcoming Evercore investor conference. LONDON, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat …Get the latest Compass Pathways PLC (CMPS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …TipRanks
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ...
These psychedelic stocks are speculative but could potentially offer massive upside. MindMed ( MNMD ): Positioned to rapidly expand its GAD therapy this year. COMPASS Pathways ( CMPS ): COMP360 ...COMPASS Pathways plc (COMPASS) operates as a mental health care company. The company engages in the development of a new model of psilocybin therapy, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support. Its initial focus is on treatment-resistant depression (TRD), a subset of major ... Apr 26, 2021 · Shares of psychedelics-inspired medicine developer COMPASS Pathways (NASDAQ: CMPS) jumped more than 5% on Monday, continuing what has been a multi-day uptrend for CMPS stock.; CMPS stock is now up ... Dec 2, 2023 · The stock spiked 2.01% in intraday trading to $6.10 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is -5.43%, and it has moved by 5.54% in 30 days. Based on these gigs, the overall price performance for the year is -40.78%. The short interest in Compass Pathways Plc ADR (NASDAQ:CMPS) is 3.91 million shares ...
We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. News & events. News releases. SEC filings & annual reports. Our annual review. Stock information. Stock quote & chart. Historical price lookup. Corporate governance.Web
View a financial market summary for CMPS including stock price quote, trading volume, volatility, options volume, statistics, and other important company ...
Nov 9, 2021 · What happened. Compass Pathways ( CMPS 6.61%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ... 10 stocks we like better than COMPASS Pathways When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, ...Discover historical prices for CMPS stock on Yahoo Finance. View daily, weekly or monthly format back to when COMPASS Pathways plc stock was issued.These psychedelic sector stocks are generating a buzz among investors. ... Compass Pathways PLC -26.3%: Incannex Healthcare Ltd. -69.6% ... Commercial Real Estate Outlook for 2024.Stock Price Forecast. The 3 analysts offering 12-month price forecasts for GameStop Corp have a median target of 18.75, with a high estimate of 20.00 and a low estimate of 6.00. The median ...9 พ.ย. 2564 ... Compass Pathways CEO on mushroom-based therapy for depression ... Global Business and Financial News, Stock Quotes, and Market Data and Analysis.
COMPASS Pathways plc (CMPS) share price prediction for 2023, 2024, 2025, 2026 and 2027. CMPS one year forecast. Compass Pathways Plc stock monthly and weekly forecasts.WebWhen a company is developing a novel therapy, sometimes good news takes an unusual form. For Compass Pathways, ( CMPS -8.84%) whose COMP360 program aims to address treatment-resistant depression ...That's true for all of the existing public psychedelic biotechs engaged in drug development, including such industry leaders as Compass Pathways (CMPS-2.26%) and Atai Life Sciences (ATAI-1.51%).TipRanksCOMPASS Pathways PLC Sponsored ADR (CMPS) Just Flashed Golden Cross Signal: Do You Buy? 09/08/23-8:55AM EST Zacks Pediatrix (MD) Down 4.2% Despite Q1 Earnings & Revenue Beat 05/05/23-11:16AM EST ZacksTipRanks
21.61M. MSFT. 377.43. -0.11%. 9.38M. View today's Compass Pathways Plc stock price and latest CMPS news and analysis. Create real-time notifications to follow any changes in the live stock price.
See COMPASS Pathways plc (CMPS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.An easy way to get COMPASS Pathways Plc - American Depository Shares real-time prices. View live CMPS depositary receipt chart, financials, and market news.markets.businessinsider.com - August 7 at 4:42 PM. HC Wainwright Reiterates "Buy" Rating for COMPASS Pathways (NASDAQ:CMPS) marketbeat.com - August 4 at 2:37 PM. Compass Pathways Plc (CMPS) Q2 2023 Earnings Call Transcript. finance.yahoo.com - August 4 at 4:00 AM. COMPASS Pathways Q2 2023: $148.2M Cash Position, Steady …Nov 13, 2023 · Future criteria checks 0/6. COMPASS Pathways's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 82.4% per year. EPS is expected to grow by 6.1% per annum. Return on equity is forecast to be -82.5% in 3 years. Compare with up to 5 Stocks. On Monday 11/06/2023 the closing price of the COMPASS Pathways PLC (spons. ADRs) share was $6.05 on NAS. Compared to the opening price on Monday 11/06/2023 on NAS of ...WebCompass Pathways jumped in its first day of trading on Friday, making it the first psychedelic drug company to go public on a big U.S. exchange.. X. Shares surged 70.6% to close at 29.00 in the ...
COMPASS Pathways (CMPS) Stock Forecast & Price Prediction. Estimation of the future price movement of COMPASS Pathways stock, based on various factors such as …
Learn More. Market Cap. (-2.86%) -$0.17. Current Price. The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic ...Web
Nov 27, 2023 · The Compass Pathways PLC stock price fell by -6.05% on the last day (Monday, 27th Nov 2023) from $6.45 to $6.06. During the last trading day the stock fluctuated 13.20% from a day low at $5.80 to a day high of $6.56. The price has risen in 6 of the last 10 days and is up by 14.99% over the past 2 weeks. Volume has increased on the last day by ... Find the latest COMPASS Pathways Plc - American CMPS analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating ... Nov 9, 2021 · What happened. Compass Pathways ( CMPS 6.61%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ... Nov 27, 2023 · The Compass Pathways PLC stock price fell by -6.05% on the last day (Monday, 27th Nov 2023) from $6.45 to $6.06. During the last trading day the stock fluctuated 13.20% from a day low at $5.80 to a day high of $6.56. The price has risen in 6 of the last 10 days and is up by 14.99% over the past 2 weeks. Volume has increased on the last day by ... Nov 27, 2023 · The Compass Pathways PLC stock price fell by -6.05% on the last day (Monday, 27th Nov 2023) from $6.45 to $6.06. During the last trading day the stock fluctuated 13.20% from a day low at $5.80 to a day high of $6.56. The price has risen in 6 of the last 10 days and is up by 14.99% over the past 2 weeks. Volume has increased on the last day by ... COMPASS Pathways Stock forecast & analyst price target predictions based on 6 analysts offering 12-months price targets for 5Y6 in the last 3 months.We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. News & events. News releases; Events; Presentations; SEC filings & annual reports; Our annual review; Stock information. Stock quote & chart; Historical price lookup; Analyst Coverage; Split history; Corporate ...The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations....CMPS With so many new IPOs and companies launching in the psychedelic industry it's important to fully evaluate...The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations....CMPS With so many new IPOs and companies launching in the psychedelic industry it's important to fully evaluate...
16 ส.ค. 2566 ... ... Price” requirement (as defined in the Nasdaq rules). COMPASS intends to use the net proceeds from the proposed financing to fund its pivotal ...May 13, 2022 · COMPASS Pathways has a market cap of $299.3 million, and a 52-week range of $6.74 to $49.52. The stock has a price/book ratio of 1.32, and a price-to-free-cash-flow ratio of -6.9. It is one of the best psychedelic stocks to invest in. On December 15, EF Hutton analyst Elemer Piros initiated coverage of COMPASS Pathways plc (NASDAQ:CMPS) with a Buy rating and a $38 price target.Instagram:https://instagram. grebadiersgov expense ratiotqqq ex dividend dateev stocks to buy COMPASS Pathways' (NASDAQ:CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant ... COMPASS Pathways' (NASDAQ:CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with...Compass Pathways PLC Stock Forecast Over the next 52 weeks, Compass Pathways PLC has on average historically fallen by 41.6% based on the past 3 years of stock performance. Compass Pathways PLC has fallen lower in 3 of those 3 years over the subsequent 52-week period, corresponding to a historical accuracy of 100% lithium refining companiesdividend ex dates Beam Therapeutics (BEAM-1.72%), COMPASS Pathways (CMPS-6.05%), ... The average price target for the stock is $41.67, implying a 382% upside potential from its current share price. Like Beam ...What happened. Compass Pathways ( CMPS 6.18%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ...Web how to purchase brics currency An easy way to get COMPASS Pathways Plc - American Depository Shares real-time prices. View live CMPS depositary receipt chart, financials, and market news.Apr 26, 2021 · Shares of psychedelics-inspired medicine developer COMPASS Pathways (NASDAQ: CMPS) jumped more than 5% on Monday, continuing what has been a multi-day uptrend for CMPS stock.; CMPS stock is now up ... What this means: InvestorsObserver gives Compass Pathways Plc ADR (CMPS) an overall rank of 34, which is below average. Compass Pathways Plc ADR is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 34 means that 66% of stocks appear more favorable to our system.